Investing.com - Tcr2 Therapeutics reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Tcr2 Therapeutics announced earnings per share of $-0.79 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.78 on revenue of $0.00.
Tcr2 Therapeutics shares are down 35% from the beginning of the year and are trading at $1.34 , down-from-52-week-high.
Tcr2 Therapeutics shares lost 2.90% in intra-day trade after the report.
Tcr2 Therapeutics follows other major Healthcare sector earnings this month
Tcr2 Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar